Citadel Advisors’s Champions Oncology CSBR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-16,326
Closed -$106K 12834
2025
Q3
$106K Buy
+16,326
New +$115K ﹤0.01% 11818
2025
Q2
Sell
-22,902
Closed -$162K 12880
2025
Q1
$199K Buy
22,902
+12,034
+111% +$122K ﹤0.01% 10451
2024
Q4
$93.1K Buy
+10,868
New +$54.7K ﹤0.01% 11582
2024
Q3
Sell
-10,218
Closed -$52.8K 14354
2024
Q2
$52.8K Sell
10,218
-2,607
-20% -$12.7K ﹤0.01% 11694
2024
Q1
$62.8K Sell
12,825
-1,802
-12% -$10.5K ﹤0.01% 11942
2023
Q4
$79.1K Buy
14,627
+3,695
+34% +$20.6K ﹤0.01% 11238
2023
Q3
$68K Sell
10,932
-4,483
-29% -$28.3K ﹤0.01% 11360
2023
Q2
$97K Buy
15,415
+2,931
+23% +$15.1K ﹤0.01% 10987
2023
Q1
$50.2K Sell
12,484
-25,533
-67% -$109K ﹤0.01% 12134
2022
Q4
$171K Buy
38,017
+704
+2% +$4.6K ﹤0.01% 10400
2022
Q3
$280K Buy
37,313
+20,716
+125% +$173K ﹤0.01% 9723
2022
Q2
$134K Buy
16,597
+518
+3% +$3.96K ﹤0.01% 11097
2022
Q1
$131K Buy
+16,079
New +$129K ﹤0.01% 12000
2016
Q4
Sell
-11,929
Closed -$20K 7315
2016
Q3
$20K Buy
+11,929
New +$22.2K ﹤0.01% 7040

Other funds holding CSBR

Citadel Advisors's CSBR Position: Q4 2025 in Review

Citadel Advisors sold out of Champions Oncology (CSBR) in Q4 2025, closing a stake of 16,326 shares — an estimated $106K sold.

Citadel Advisors first reported a position in CSBR in Q3 2016 and held it in 14 quarters. The position peaked at $280K in Q3 2022. 27 funds tracked by Wall St. Rank hold CSBR as of Q4 2025.

  • Citadel Advisors reported no remaining Champions Oncology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 16,326 Champions Oncology shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and held it in 14 quarters.
  • Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.